Botanical species · safety record

Cryptostegia grandiflora

The EFSA Compendium of Botanicals holds 10 constituent measurements and 5 adverse-effect records for Cryptostegia grandiflora. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Cryptostegia grandiflora Roxb. ex R.Br.

10Constituent measurements

5Safety records

7Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
3,4-dihydroxybenzoic acid	Leaves	Solvent extraction	35.22 Microgram/gram	UHPLC-MS-MS	Resolve DOI
4-hydroxybenzoic acid	Leaves	Solvent extraction	12.33 Microgram/gram	UHPLC-MS-MS	Resolve DOI
Cardenolides	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Cardiac glycosides	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Gallic acid	Leaves	Solvent extraction	48.33 Microgram/gram	UHPLC-MS-MS	Resolve DOI
P-coumaric acid	Leaves	Solvent extraction	10.25 Microgram/gram	UHPLC-MS-MS	Resolve DOI
Acanthoside b	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Cardiac glycosides	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Gitoxigenin	Fruit unspecified	—	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	No resolvable identifier
Oleandrigenin	Fruit unspecified	—	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Digestive	Heart	Leaves	Solvent extraction	Human (as organism)	Case report	No resolvable identifier
Not reported	—	Leaves	Solvent extraction	Sheep (as animal)	Short-term toxicity	No resolvable identifier
Not reported	—	Leaves	Solvent extraction	Sheep (as animal)	Short-term toxicity	No resolvable identifier
Pulmonary and cardiac	Cardiovascular / haematological	Leaves	Solvent extraction	Cattle (as animal)	Short-term toxicity	No resolvable identifier
Pulmonary and cardiac	Heart	Leaves	Fresh	Mammals (as animal)	Case report	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

McGavin, M. D. Rubbervine (Cryptostegia grandiflora) toxicity for ruminants. Queensland journal of agricultural and animal sciences, 1969, vol. 26, no. 1, p. 9-19.
BRAIN, C., FOX, VEB. SUSPECTED CARDIAC GLYCOSIDE POISONING IN ELEPHANTS (LOXODONTA-AFRICANA). Journal of the south african veterinary association-tydskrif van die suid-afrikaanse veterinere vereniging, 1994, vol. 65, no. 4, p. 173-174.
Prabakaran, Mayakrishnan., Kim, Seung-Hyun., Hemapriya, Venkatesan., Chung, Ill-Min. Evaluation of polyphenol composition and anti-corrosion properties of Cryptostegia grandiflora plant extract on mild steel in acidic medium . Journal of industrial and engineering chemistry, 2016, vol. 37, p. 47-56. DOI
Assaf, M. H., Kamel, M. S., Bishay, D. W. Phenolic and aliphatic glucosides from Cryptostegia grandiflora and cardiotonic activity of cryptostigmin II. Bulletin of pharmaceutical sciences, assiut university, 2003, vol. 26, no. 1, p. 41-48.
El Zalabani, S. M., Abdel Sattar, E. A., Fathy, F. I., Shehab, N. G. Phytochemical study of flowers and latex of Cryptostegia grandiflora R.Br. cultivated in Egypt. Bulletin of the faculty of pharmacy (cairo university), 2004, vol. 42, no. 2, p. 159-169.
Kamel, MS., Assaf, MH., Abe, Y., Ohtani, K., Kasai, R., Yamasaki, K. Cardiac glycosides from Cryptostegia grandiflora. Phytochemistry, 2001, vol. 58, no. 4, p. 537-542. DOI
Sangle, Shashikala A., Inamdar, Sonali., Deshmukh, Vikrant. Cryptostegia grandiflora Toxicity Manifesting as Hyperkalemia, Complete Heart Block and Thrombocytopenia. . The journal of the association of physicians of india, 2015, vol. 63, no. 5, p. 79-81.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature